Floatz logo

FMISO

Adult Giant Cell Glioblastoma

National Cancer Institute (NCI)Small moleculePhase 2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
35/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Adult Giant Cell Glioblastoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Case Comprehensive Cancer Center
Phase 2BBB
Cediranib
Lawrence Recht
Phase 2BBB
Temsirolimus
National Cancer Institute (NCI)
Phase 2BBB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 2BB
Sorafenib
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

FMISO is also rated in:

triple-negative breast carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
50 / 100
View asset →
adult glioblastomaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →